Molybdenum Deficiency and Eye Health
Molybdenum deficiency does NOT cause clinically significant eye problems in typical nutritional deficiency states, but genetic molybdenum cofactor deficiency (MoCD) causes severe ocular manifestations including lens dislocation (ectopia lentis).
Understanding the Critical Distinction
The answer depends entirely on whether we're discussing:
1. Acquired Nutritional Molybdenum Deficiency (Extremely Rare)
- No documented ocular effects in the single reported case of acquired deficiency 1
- The ESPEN 2022 guidelines note that molybdenum measurement is "rarely required" and should only be assessed in suspected deficiency cases 1
- The one documented case of acquired deficiency (prolonged TPN patient) presented with tachycardia, headache, mental disturbances, and coma—no eye manifestations were reported 2
- Molybdenum deficiency is essentially non-existent in free-living humans due to 90% intestinal absorption efficiency and widespread food availability 1
2. Genetic Molybdenum Cofactor Deficiency (MoCD) (Severe Ocular Impact)
This is an entirely different entity—an inborn error of metabolism, not a nutritional deficiency.
Ocular manifestations in MoCD include:
- Ectopia lentis (lens dislocation) - the hallmark ocular finding 3, 2, 4
- Spherophakia (spherical lens shape) 3
- Secondary glaucoma 3
- Cyclodialysis 3
- Retinal detachment 3
- Visual impairment of varying degrees 4, 5
Clinical Context and Mechanism
Why MoCD affects the eyes but nutritional deficiency doesn't:
MoCD causes deficiency of sulfite oxidase (SO), one of four molybdenum-dependent enzymes. The resulting sulfite toxicity and inadequate sulfate formation for brain and connective tissue development causes the severe manifestations 2, 6. Patients with isolated SO deficiency or molybdenum cofactor deficiency exhibit mental retardation, neurologic problems, and ocular lens dislocation due to sulfite toxicity 2.
The disease typically presents in the neonatal period (median 2-4 days) with intractable seizures (60.3%), feeding difficulties (53.4%), and rapidly progressive neurodegeneration 5. One-year survival is only 71-77% 5.
Clinical Pitfalls
Do not confuse:
- Nutritional molybdenum deficiency (virtually non-existent, no eye effects)
- MoCD (genetic disease, severe eye and neurologic effects)
When to suspect MoCD:
- Neonatal seizures with lens dislocation
- Low serum/urine uric acid with high xanthine and S-sulfocysteine 5, 6
- MRI showing symmetrical globus pallidus involvement with cerebral infarction 4
Bottom Line for Clinical Practice
For nutritional assessment: Molybdenum deficiency is not a concern for eye health in typical clinical scenarios. The ESPEN guidelines emphasize measurement is "rarely required" 1.
For genetic disease: If you encounter a patient with ectopia lentis plus neurologic symptoms, consider MoCD in the differential diagnosis and measure urine sulfite, hypoxanthine, xanthine, and plasma uric acid 1. Early diagnosis enables genetic counseling and, for MoCD type A specifically, potential treatment with cyclic pyranopterin monophosphate (cPMP) 6.